United Bank Acquires New Holdings in Bristol Myers Squibb Company $BMY

United Bank bought a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 28,828 shares of the biopharmaceutical company's stock, valued at approximately $1,661,000.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company's stock valued at $10,719,376,000 after purchasing an additional 2,743,759 shares during the period. BlackRock Inc. lifted its stake in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock valued at $10,393,783,000 after buying an additional 8,702,106 shares in the last quarter. State Street Corp boosted its holdings in shares of Bristol Myers Squibb by 1.4% in the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company's stock valued at $5,285,065,000 after buying an additional 1,385,206 shares during the period. Geode Capital Management LLC increased its position in shares of Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock worth $2,837,026,000 after acquiring an additional 6,084,046 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $1,947,272,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $67.59 on Thursday. The stock has a market capitalization of $138.06 billion, a price-to-earnings ratio of 14.89, a PEG ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.64. The firm has a fifty day simple moving average of $60.18 and a 200 day simple moving average of $59.24. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period in the previous year, the business earned $1.46 EPS. The company's revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.7%. Bristol Myers Squibb's payout ratio is currently 55.51%.

Analysts Set New Price Targets

BMY has been the topic of several research reports. Raymond James Financial started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a "strong-buy" rating on the stock. Guggenheim reissued a "buy" rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. TD Cowen began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a "buy" rating on the stock. Sanford C. Bernstein raised Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research report on Wednesday, August 5th. Finally, BMO Capital Markets reiterated a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source